Conrad Leung, PhD

Dr. Conrad Leung currently serves as the Chief Scientific Officer at Couragene. He joined the company in April 2023 and is responsible for overseeing research and development activities.

Conrad has more than 17 years of experience in the Life Science industry. Prior to joining Couragene, Conrad was the Chief Scientific Officer at GENEWIZ, a leading global genomics service provider for pharmaceutical, biotechnology and academic institutions. At GENEWIZ, Conrad led a team of scientists to develop innovative technologies for genomic research. His works supported the growth of GENEWIZ to a company with $130M+ yearly revenue when it was acquired by Brooks Automation in 2018. Before joining GENEWIZ, Conrad was an Assistant Professor at Columbia University where his research focused on neurodegenerative diseases, including Alzheimer’s and Amyotrophic Lateral Sclerosis. He has co-authored numerous publications and patents related to genomics and pathogenesis of neurological diseases.

Conrad graduated with a bachelor’s degree in Biochemistry from UC Davis and a Ph.D. in Biochemistry and Molecular Biophysics from Columbia University.